scholarly journals Valvular heart diseases. The late results of surgical treatment of mitral valve disease with cardiac cachexia.

1991 ◽  
Vol 20 (5) ◽  
pp. 938-940
Author(s):  
M. Otaki
Keyword(s):  
Surgical Treatment ◽  
Mitral Valve ◽  
Mitral Valve Disease ◽  
Heart Diseases ◽  
Late Results ◽  
Valve Disease ◽  
Cardiac Cachexia ◽  
Valvular Heart Diseases

scholarly journals Surgical treatment of congenital mitral valve disease: Midterm results of a repair-oriented policy

2008 ◽  
Vol 135 (6) ◽  
pp. 1313-1321.e4 ◽  
Author(s):  
Guido Oppido ◽  
Ben Davies ◽  
D. Michael McMullan ◽  
Andrew D. Cochrane ◽  
Michael M.H. Cheung ◽  
...  
Keyword(s):  
Surgical Treatment ◽  
Mitral Valve ◽  
Mitral Valve Disease ◽  
Valve Disease ◽  
Midterm Results ◽  
Congenital Mitral Valve Disease

Mitral valve disease in young; Review of surgical treatment

1983 ◽  
Vol 2 (1) ◽  
pp. 29-35 ◽  
Author(s):  
S. K. Chadha ◽  
R. N. Thareja ◽  
M. Durairaj ◽  
V. M. Alurkar ◽  
S. D. Palnitkar ◽  
...  
Keyword(s):  
Surgical Treatment ◽  
Mitral Valve ◽  
Mitral Valve Disease ◽  
Valve Disease

scholarly journals Diagnostic value of echocardiographic indices of left atrial and ventricular morphology in dogs with myxomatous mitral valve disease (MMVD)

2021 ◽  
Vol 4 (1) ◽  
pp. 16-23
Author(s):  
R. M. Trofimiak ◽  
L. G. Slivinska
Keyword(s):  
Mitral Valve ◽  
Mitral Valve Disease ◽  
Left Atrial ◽  
Heart Diseases ◽  
Diagnostic Technique ◽  
Diagnostic Value ◽  
Left Ventricular ◽  
Clinical Diagnostics ◽  
Valve Disease ◽  
Mitral Apparatus

Myxomatous mitral valve disease (MMVD) is one of the most common acquired diseases of the cardiovascular system of genetic etiology in small breed dogs. A long asymptomatic course characterizes the disease. Presently, the main diagnostic technique for heart diseases is echocardiography. This study evaluates individual echocardiographic indices of the left atrial and ventricular morphology with the determination of the diagnostic value of each of them in predicting the course of the disease. The study was conducted in a private veterinary hospital “Eurovet” and on the basis of the clinic of the Department of internal animal diseases and clinical diagnostics of Stepan Gzhytskyi National University of Veterinary Medicine and Biotechnology Lviv during 2018–2019. The objects consisted of 46 dogs with a confirmed diagnosis of myxomatous mitral valve disease according to the recommendations of the American College of Veterinary Internal Medicine (ACVIM) and no signs of comorbidities. During the study, three experimental groups of animals were formed according to the clinical and functional status characteristic of each stage of MMVD development – B1, B2, C. According to the results, all experimental dogs showed changes in the mitral apparatus in the form of thickening of the anterior and posterior cusps, mitral valve (MV) prolapse into the left atrial (LA) cavity and regurgitation (MR), the severity of which increased with the stage of the disease (from 20 % to 60 %). In 44.4 % of animals in group B2, thickening of the left ventricular walls was diagnosed in diastole and in 22.2 % in systole. Instead, these values increase to 46.1 % and 53.8 % in group C, respectively. However, the degree of hypertrophy is disproportionate. With the development of the disease, we detect its decrease from 0.64 ± 0.03 (group B1) to 0.50 ± 0.04 (group B2) and 0.51 ± 0.03 (group C) also we observed an increase in LVEDD/2 from 1.30 ± 0.05 cm (group B1) to 1.46 ± 0.12 cm (group B2) and 1.54 ± 0.13 cm (group C). The value of nLVEDD in B1 was 1.36 times (P < 0.001) lower compared to B2 and C. Higher values of this parameter were found in 23.1 % of dogs in group C compared to the maximum value of B2. As MV insufficiency progresses, the LA/Ao index increases slightly (1.08 times) in B2, followed by an increase in C (1.38 times, P < 0.001). At the same time, we diagnose an increase (P < 0.05) in PV/PA by 1.18 times in B2 and 1.46 times (P < 0.001) in C. Thus, an increase in the severity of mitral regurgitation, a rapid increase in nLVEDD, the dynamics of the decrease in the degree of hypertrophy h/R, as well as an increase in LA/AO, PV/PA indices are predictors of unfavorable prognosis of myxomatous degeneration of the mitral valve in dogs.

scholarly journals Simultaneous Surgical Treatment for Atrial Fibrillation and Mitral Valve Disease.

1994 ◽  
Vol 23 (3) ◽  
pp. 172-178 ◽  
Author(s):  
Shigeo Yamauchi ◽  
Tetsuo Asano ◽  
Atsushi Harada ◽  
Masatoshi Ikeshita ◽  
Shigeo Tanaka ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Surgical Treatment ◽  
Mitral Valve ◽  
Mitral Valve Disease ◽  
Valve Disease

Surgical Treatment of Mitral Valve Disease

1983 ◽  
Vol 76 (6) ◽  
pp. 703-705 ◽  
Author(s):  
R. VIJAYANAGAR ◽  
DIEGO BOGNOLO ◽  
PAUL ECKSTEIN ◽  
DIANE JEFFERY ◽  
JOHN TOOLE ◽  
...  
Keyword(s):  
Surgical Treatment ◽  
Mitral Valve ◽  
Mitral Valve Disease ◽  
Valve Disease

scholarly journals Circulating Galectin-3 Evaluation in Dogs With Cardiac and Non-cardiac Diseases

2021 ◽  
Vol 8 ◽  
Author(s):  
Ga-Won Lee ◽  
Min-Hee Kang ◽  
Woong-Bin Ro ◽  
Doo-Won Song ◽  
Hee-Myung Park
Keyword(s):  
Mitral Valve ◽  
Cardiac Disease ◽  
Mitral Valve Disease ◽  
Large Scale ◽  
Heart Diseases ◽  
Ductus Arteriosus ◽  
Valve Disease ◽  
Enzyme Linked Immunosorbent Assay ◽  
Galectin 3 ◽  
Healthy Dogs

Galectin-3 is involved in important biological functions such as fibrogenesis and inflammation. Notably, it is associated with various diseases and plays a major role in cardiac inflammation and fibrosis. Although heart diseases are relatively common in dogs, a few studies have analyzed the circulating galectin-3 concentration in dogs with various heart diseases, including myxomatous mitral valve disease, patent ductus arteriosus, and pulmonic stenosis. The aims of the present study were to evaluate the effect of heart disease on circulating galectin-3 levels in dogs, and also to evaluate the correlation between galectin-3 concentration and conventional echocardiographic indices along with N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration in dogs with heart diseases. The medical records and archived serum samples of 107 dogs were evaluated retrospectively. In total, 107 dogs were classified into healthy dogs (n = 8), cardiac disease (n = 26), and non-cardiac disease groups (n = 73). The circulatory galectin-3 levels were analyzed using a commercially available canine-specific galectin-3 enzyme-linked immunosorbent assay kit. This study demonstrated that dogs with heart, endocrine, and dermatologic diseases had significantly higher galectin-3 levels than healthy dogs (p = 0.009, p = 0.007, and p = 0.026, respectively). Among dogs with heart diseases, dogs with concentric cardiomyopathy had significantly increased circulatory galectin-3 levels compared with healthy dogs (p = 0.028). E′/A′ had a positive association with galectin-3 levels among conventional echocardiographic indices. Moreover, the galectin-3 concentration could predict diastolic dysfunction. In dogs with myxomatous mitral valve disease, a significantly positive correlation was revealed between galectin-3 levels and NT-proBNP levels (p = 0.007). Overall, this study demonstrates that circulatory galectin-3 levels increase in dogs with heart, endocrine, and dermatologic diseases. Moreover, this study demonstrates that galectin-3 concentration could be helpful to evaluate cardiac remodeling and diastolic function. Further large-scale research is required to evaluate the role of circulating galectin-3 in dogs with heart diseases.

Sign in / Sign up

Export Citation Format

Share Document